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Abstract
Muscle cells must anchor to their environment, the extracellular matrix (ECM), in
order to function properly. Muscular dystrophy occurs when muscle cells cannot anchor
to the ECM because specific protein complexes, such as the dystroglycan complex, are
disrupted. Previously published studies have shown that overexpressing Paxillin can
reduce dystrophy in dag1 deficient embryos. The aim of this study is to determine which
domains of Paxillin are necessary to rescue dystrophy by overexpressing Paxillin with the
LD2 or LD4 domains knocked out in dystrophic embryos. However, disruption of Dag1
via the previous method stopped producing the muscular dystrophy phenotype, so ethanol
(EtOH) treatment was used to induce dystrophy. It was determined that this is not a
sufficient method of inducing dystrophy for this study. The EtOH treatment was
inconsistent, and Paxillin overexpression was unable to rescue dystrophy in EtOH treated
zebrafish. Furthermore, the dystrophy seen in EtOH treated embryos was much more
severe than that seen in typical muscular dystrophy. Although this experiment could not
be used to determine the necessity of the LD domains of Paxillin, it did give insight into
the toxicity of EtOH. This information will be useful as we move on using different
techniques.
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Introduction
Cells are the building blocks of our body and it is critical to our survival that they
function properly, but most cells cannot do this if they are not anchored to their
environment (the extracellular matrix or ECM). This ECM is the substance that lies
between cells and contains many proteins that act as a point of attachment for cells.[1]
This requirement for attaching to the ECM is especially true of muscle cells, which
function by continuously contracting and relaxing; exhibiting a force on their
environment. Thus, muscle cells cannot function in voluntary movement of the body on
their own and must have some component to anchor them.[2] This component is the
myotendinous junction (MTJ), where muscles anchor to tendons. The MTJ is rich in
extracellular matrix. During zebrafish early embryonic muscle development small
precursor cells elongate to the MTJ and then bind to ECM proteins at the MTJ as an
anchor.[3]
Two of the major types of macromolecules found within the ECM are the
proteoglycans, a gel like substance that fills the interstitial space between the proteins,
and the fibrous proteins, mostly collagens, elastins, fibronectins, and laminins.[4] Many of
these adhesion proteins are found within a subunit of the ECM called the basement
membrane. Of particular importance is laminin, which is a cross-shaped protein found
within the basal lamina of the basement membrane. It is involved in binding the
intracellular actin cytoskeleton of the muscle cell to the basement membrane of the MTJ.
This attachment can either occur through laminin binding to transmembrane integrin
proteins of the cell, or through laminin binding to the dystroglycan complex (DGC).

1

The DGC is a transmembrane protein complex consisting of alpha and beta
subunits. The intracellular β-dystroglycan subunit lies within the membrane and binds to
a rod-shaped protein called dystrophin in the cytosol of the cell.[5] Dystrophin anchors βdystroglycan to actin within the cytoskeleton. The α-dystroglycan subunit binds to βdystroglycan within the membrane, but also has a region that lies outside of the
membrane and links to laminin. The LG4-5 tail region of laminin binds to the highly
glycosylated α-dystroglycan subunit while the alpha-1 LN at the top of laminin binds to
type IV collagen in the BM.[6]
There are multiple pathologies that result from a disruption of this attachment.
This is the case in many of the congenital muscular dystrophies (CMD) including
Duchenne (DMD) and Becker muscular dystrophies, which have a mutation in
dystrophin. These are x-linked recessive diseases that appear most frequently in young
males.[7] The major symptom is muscle wasting, which can become so severe that it
limits lung and cardiac function. Children are typically diagnosed between three and five
years of age, and in the case of DMD generally have a short life expectancy of about 25
years. Becker muscular dystrophy is caused by a different dystrophin allele, is milder,
and occurs less frequently.[5]
In both variations of the disease the mutation on the X chromosome is for the
intracellular protein dystrophin.[5] When this is altered or missing β-dystroglycan is
unable to anchor to the actin cytoskeleton. With use, the muscle cell-BM attachment
and/or the muscle membrane tear, and the muscle cells recoil and degenerate. This results
in atrophy of the muscle that worsens over time, generally causing significant reduction
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in muscle mass. The severity varies depending on the individual and on the type of
dystrophy, but in many cases their life is severely impaired.
An excellent model for studying muscular dystrophies is the zebrafish. Zebrafish
have external fertilization, which makes them ideal compared to other model organisms,
such as mice, that gestate in utero. This form of reproduction allows us to view and
manipulate early stages of development beginning at fertilization. Zebrafish also have
translucent bodies, making visibility of muscle segmentation distinctly clear even under a
simple dissecting microscope. Above all of this, the zebrafish share 70% of the same
DNA as humans [8] and display the same phenotypes for congenital muscular dystrophies.
This includes conserved sequences for dystrophin and dystroglycan across humans and
zebrafish.
Recent studies have used zebrafish as a model to study the relationship between
muscle cells and the MTJ as a way to treat dystrophy. The Henry lab has shown how
activating the Nrk2b pathway can result in increased polymerization of laminin at the
MTJ and improved muscle cell attachment. This involved supplementing exogenous
NAD+ precursors to Dag1 morphants, which are embryos that lack dystroglycan and
express symptoms of a type of muscular dystrophy known as dystroglycanopathy. This
treatment was successful in improving both muscle health and motility [9]. Paxillin, which
is a cell adhesion molecule found downstream of the NAD+ pathway, was also
discovered to contribute to a reduction in muscle fiber detachments when the gene for it
was overexpressed in Dag1 morphants. Dag1 morphant embryos showed improved
muscle health as well as increased organization of laminin at the MTJ. Paxillin
overexpression did not, however, rescue motility [9].
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This elicited some curiosity in how Paxillin is acting within the cell; specifically
how it is contributing to laminin polymerization. This is the central question behind this
research. Paxillin is a cell adhesion molecule that is believed to be involved in multiple
signaling pathways. There are several domains within Paxillin, several of which act as
docking sites for other proteins [10]. One such example is with the integrins, but it is
unclear what the mechanisms are behind this relationship. The study done by Goody et al.
displayed a correlation between increased Paxillin and increased polymerization and
organization of laminin at the MTJ. Understanding the mechanisms behind this could
potentially lead to new opportunities in treatment of muscular dystrophy.
One way to glean this information would be to look at each domain of Paxillin
and determine which ones are contributing to its ability to ameliorate dystrophy. This
could be done by overexpressing Paxillin with specific domains knocked out in a
transgenic embryo and looking to see if dystrophy is still rescued. Once it is determined
which domains are necessary it would be possible to look at the proteins that interact with
those domains. With this knowledge, we could look downstream of the signaling
pathways of those proteins to come up with a mechanism. Thus, the purpose of this
thesis is to investigate domains of Paxillin that play a critical role in ameliorating
muscular dystrophy.

4

Materials and Methods
Zebrafish Husbandry:
Zebrafish were set up for natural spawning in a facility that is kept on a 16-hour
light/8-hour dark cycle. The zebrafish lines of interest that were used for this study were
transgenic for overexpression of Paxillin. This process involves inserting a transgene
(such as Paxillin with a domain knocked out) into the single celled embryonic stage. The
transgene is intended to be inserted wherever there are transposable elements within the
genome. However, it is not a perfect system and the transgene does not always get
inserted. Furthermore, in order to be passed on to the next generation the transgene must
be inserted into an autosome. It is not guaranteed that this process will be successful, thus
it is necessary to cross male and female pairs and identify the embryos as carriers of the
transgene. The inserted Paxillin transgene is tagged with green fluorescent protein (GFP),
which fluoresces under a UV microscope. This is used to identify carriers.
Once a male and female pair has been identified as carriers of the transgene they
are moved into a new tank. The offspring that also carry the transgene can then be reared
and breed within a few months. The first part of this thesis was to identify the carriers of
the transgene that would be used for further studies. Eggs from these identified parents
were collected in the morning and kept in embryo rearing medium (ERM) in a 28 ̊ C
incubator.
Investigating Different Ethanol (EtOH) Dosages
Preliminary research was required to determine the dilution of EtOH that was
sufficient for inducing fiber detachment in the embryos. Embryos were reared in different
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solutions of varying dilutions of ERM:EtOH across two different lines of Paxillin
transgenics: HS Paxillin GFP (green fluorescent protein) and β-actin Paxillin GFP.
The β-actin Paxillin embryos were divided into four groups: 0% EtOH, 1.5%
EtOH, 1.75% EtOH, and 2% EtOH. To make each solution 200 proof EtOH stock
solution was diluted in ERM. Embryos were reared in pure 1x ERM immediately
following egg collection and were transferred to the EtOH solution at 24hpf (hours post
fertilization). The EtOH solution was changed with fresh solution daily and dead
embryos and empty chorions were removed. The embryos were fixed at 72hpf. All the
embryos fluoresced positive for GFP, thus there were no wild type controls for this trial.
There was a much lower yield of HS Paxillin embryos than β-actin Paxillin, so it
was only possible to use two groups. These were 1.75% EtOH heat-shocked embryos,
and 1.75% EtOH non heat-shocked embryos. Heat-shocking is necessary to activate the
overexpression of Paxillin. 24 hpf embryos were heat-shocked in an incubator at 42 ̊ C
for one hour and 30 minutes. Since there was such a low yield of embryos there were no
0% EtOH controls.
Investigating the Necessity of the Paxillin LD2 Domain in Ameliorating Dystrophy:
The HS Paxillin (-LD2) GFP transgenics overexpress Paxillin with the LD2
domain knocked out. They were divided into four groups: 0% EtOH heat shocked, 0%
EtOH no heat-shock (controls), 2% EtOH heat-shocked, and 2% EtOH no heat-shock. To
make each solution 200 proof EtOH stock solution was diluted in ERM. Embryos were
reared in pure 1x ERM immediately following egg collection. The embryos were heatshocked at 42 ̊ C for one hour and 30 minutes, and then immediately transferred to the
2% EtOH solution. The EtOH solution was changed daily and dead embryos and empty
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chorions were removed. The embryos were fixed at 72hpf. Not all of the heat-shocked
embryos fluoresced positive for GFP under a fluorescent light, thus some controls were
also built into the trial.
Investigating Paxillin Overexpression with LD2 or LD4 Domain Knock-outs:
Three lines of Paxillin transgenics were used for this trial: HS Paxillin GFP, HS
Paxillin (-LD2) GFP, and HS Paxillin (-LD4) GFP. Each line was divided into two
groups: 0% EtOH heat-shocked and 2% EtOH heat-shocked. The embryos were heatshocked at 42 ̊ C for one hour and 30 minutes, and then transferred to the 2% EtOH
solution. This solution was made by diluting 200 proof EtOH stock solution in 1x ERM.
The EtOH solution was changed daily and dead embryos and empty chorions were
removed. The embryos were fixed at 72hpf.
Immunofluorescent Staining:
The embryos are contained within a thin membrane called the chorion at
fertilization, but most break out of this by 72hpf. The chorion was manually removed
with forceps for those that had not, and the embryos were added to tubes in groups of 1015. This prevents the embryos from fixating in a curled position, and makes imaging
much cleaner. The embryos were fixed in 4% paraformaldehyde (PFA) for four hours at
room temperature on a rocker, or overnight at 4 ̊ C. This was followed by rinsing five
times for five minutes each in PBS-0.1% Tween20 (PBS-Tw) on a rocker. The embryos
were then permeabilized in PBS- 2% Triton (PBS-Tx) solution for one and a half hours
on a rocker.
Immediately following permeabilization 20µL of 1:20 dilution of Phalloidin:
Alexa fluor 546:PBS-Tw were added to each tube. The tubes were kept under foil from
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this point forth since phalloidin degrades under light. The embryos were phalloidin
stained either from 2-4 hours at room temperature on a rocker, or overnight at 4 ̊ C. They
were then rinsed in PBS-Tw for five times for five minutes each.
Imaging:
It is necessary to remove the yolk from the embryos and sever the head before
attempting to image them as this will facilitate clear images by allowing the embryos to
lie flat. The yolk was removed in 1% PBS with small dissecting pins. The embryos were
then mounted on a slide in 20% PBS/80% glycerol. The embryos were imaged with a
Zeiss Axio Imager Z1 microscope with a Zeiss ApoTome attachment. Images were taken
at the 20x objective with five frame averaging.
Z-stack images were obtained at 0.55µm thick slices with several filters. A
rhodamine filter was used to view the F-actin in the muscle cells that were phalloidin
stained and depicted in red. The green staining is showing the GFP tag on Paxillin with
the LD2 domain knocked out.
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Results
In order to determine which domains of Paxillin are important to ameliorate
dystrophy we need a zebrafish model of muscular dystrophy. Unfortunately, around the
time I began this research, the standard Henry lab technique for generating zebrafish with
muscular dystrophy stopped working (we used morpholinos and the company changed its
purification methods rendering them more useful for cell culture experiments but more
toxic in zebrafish). Thus, I needed a new way to generate dystrophy. I turned towards
using EtOH exposure as a way to induce dystrophy in the zebrafish. Most of the current
research on EtOH has been on pre-muscle development for the purpose of studying fetal
alcohol syndrome. The Henry Lab has been interested in the effects of EtOH in postmuscle development. Preliminary studies have shown that adding EtOH after 24hpf can
induce dystrophy in wildtype zebrafish. This will be a useful technique for studying
dystrophy since EtOH is both easy to use and readily available.
Dystrophy can then be measured by the number of embryos that display fiber
detachments as well as the overall percent of myotomes that have fiber detachments in
each embryo. These measurements would then be indicative of the ability of Paxillin to
ameliorate dystrophy. Comparisons can be made between zebrafish with different
domains knocked out as well as to zebrafish that are expressing the complete Paxillin
sequence.
Overview of Transgenics and Treatments:
We have multiple controls for these experiments. β-actin Paxillin zebrafish
express Paxillin from a constitutive (always active) promoter. Alternatively, HS promoter
allows us to control when during muscle development Paxillin is turned on by heat
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shocking the embryos. However, we also need a group of zebrafish transgenic for HS
Paxillin that are controls and are not heat shocked. We will refer to these as non-heat
shocked Paxillins.
Investigating Different EtOH Dosages:
Before we could begin to test the efficacy of Paxillin with different domains
knocked out we had to determine what dose of EtOH would be sufficient to induce
dystrophy. The β-actin Paxillin control group that was not treated with EtOH showed no
adverse muscle development, as expected. The β-actins treated with 1.5% EtOH also had
healthy muscle with no fiber detachments (fig 4). The 1.75% EtOH treated β-actins
however had 17.6% occurrence of dystrophy across all embryos at n = 28. The HS
Paxillin embryos that were heat-shocked and treated with the same 1.75 % EtOH dose
only had a 3% occurrence of dystrophy at n = 32. This result was initially exciting, but
then analyzing the other control group, the non-heat shocked Paxillins at 1.75% EtOH,
showed normal muscle development with no fiber detachments. Thus, because the nonheat shock Paxillin controls did not show dystrophy it is difficult to make any
conclusions from this experiment.
The β-actin Paxillins that were treated with a 2% EtOH dilution also had a 17.6%
occurrence of dystrophy across all embryos at n = 28 (fig 2). Embryos from this group
that did not have fiber detachments displayed abnormally curvy muscle cells (fig 3).
Although the β-actin Paxillins displayed more dystrophy with EtOH treatment than the
HS Paxillins, the Henry Lab only has transgenics with different domains of Paxillin
knocked out with the HS promoter. Since all of the subsequent studies would involve
domain knock outs it was decided to use a 2% EtOH dilution for future studies since
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1.75% EtOH treatment had too low of an occurrence of dystrophy in the HS Paxillins.
Figure 4 shows a complete comparison.
Investigating the Necessity of the Paxillin LD2 Domain in Ameliorating Dystrophy:
One of the domains of Paxillin that we predicted might play a role in rescuing
dystrophy is the LD2 domain. I was interested in this domain because it has been
recognized as acting as a docking site for focal adhesion kinase (FAK).[13] Thus, if
Paxillin is unable to rescue dystrophy with the LD2 domain knocked out that would
indicate that FAK may be involved downstream of the signaling pathway. Unfortunately,
this experiment is also difficult to interpret because of contamination of the dishes. We
have found that sometimes contamination can cause aberrant development that is not
specific to the treatment/mutation we are trying to study.
At 24hpf all the petri dishes had contamination. Most were in the control dishes
but some were in the EtOH treated dishes as well. This may affect the results. The nonheat shocked HS Paxillin embryos with no EtOH treatment acted as the controls for this
experiment. As expected, both the wild type and the fluorescing (signifying they are
transgenic) embryos had no fiber detachments (fig 5) since they were not treated with
EtOH. The heat shocked HS Paxillins had a 6% occurrence of dystrophy across all
embryos at n = 18. This 6% is a bit misleading because it is all due to the fact that one
embryo had fiber detachments on four myotomes (fig 6). ). This outlier could have
occurred because the heat shock treatment done at 42 ̊ C for 1.5 hours, which could be
too severe. One other reason could be that a number of the genes that promote muscle
cell adhesion to laminin are maternally expressed.[11] Thus, if the mother does not happen
to deposit enough RNA and proteins in the eggs they will be more likely to show
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dystrophy. Some other unknown event may have resulted in dystrophy in this embryo as
well, but regardless of the reason for the outlier, 17/18 embryos had normal muscle
development.
The next part of this experiment was to heat shock the HS Paxillin (-LD2)
embryos that have the LD2 domain knocked out and compare them to HS Paxillin
embryos with full length Paxillin. The heat-shocked HS Paxillin (-LD2) GFP embryos
that were treated with 2% EtOH and did not fluoresce, meaning they weren’t
overexpressing Paxillin with the LD2 domain knocked-out, had a 52% occurrence of
dystrophy across all embryos at n = 25 (fig 7). The average number of myotomes with
fiber detachments was 3.76 myotomes (fig 8). This average was low since it takes into
account all the embryos in the group that had no fiber detachments, however many of the
affected embryos had extremely severe dystrophy with as many as 19 myotomes with
dystrophy (fig 9). We do not understand the etiology of this variation, but some potential
causes of this variability will be considered in the discussion.
The experimental embryos are those that express HS Paxillin (– LD2) and
fluoresced, indicating that they are GFP positive and transgenic. If dystrophy is still
rescued with the LD2 domain knocked out, then that domain is not necessary for
amelioration of dystrophy. Unfortunately, in this experiment, there were only two
embryos that fluoresced. The heat-shocked HS Paxillin (-LD2) GFP embryos that were
treated with 2% EtOH and fluoresced had a 50% occurrence of dystrophy n = 2. The one
embryo with fiber detachments shown in figure 10 (red showing F-actin and green
showing GFP) had the same severity of dystrophy as the non-fluorescing group had. This
embryo had 19 myotomes with fiber detachments.
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Investigating Paxillin Overexpression with LD2 or LD4 Domain Knock-outs:
Another domain of Paxillin that we predicted might play a role in rescuing
dystrophy is the LD4 domain. Fibroblasts that express the LD4 domain have been
associated with poor focal adhesion, thus we predict that knocking out this domain may
actually make Paxillin more efficient in ameliorating dystrophy. This domain is also a
docking site for FAK, just like the LD2 domain, and has the potential for downstream
signaling.[13] This experiment also retested 2% EtOH treatment on the HS Paxillin (-LD2)
and HS Paxillin embryos. However, at 72hpf both the HS Paxillin (-LD4) and HS
Paxillin (-LD2) embryos that were treated with 2% EtOH were dead. These embryos had
been alive at 48hpf when the EtOH solution was changed. Since the breeding zebrafish
with the Paxillin LD4 domain knock out were so young and still growing, we were
unable to obtain another spawn from them. Thus, no further testing with the LD4 knock
out was completed in this study.
The HS Paxillin embryos with 2% EtOH survived and were used for further
analysis. The heat shocked HS Paxillin controls with no EtOH treatment had no fiber
detachments at n = 10 embryos (fig 11). The heat shocked HS Paxillin embryos that were
treated with 2% EtOH and fluoresced (were transgenics) had a 60% occurrence of
dystrophy across all embryos at n = 10. Those that had fiber detachments appeared to be
just as severe as the HS Paxillin (-LD2) embryos from the previous experiment (fig 12).
A comparison of the occurrence of dystrophy for both groups is shown in figure 13. All
of the EtOH treated embryos from each experiment had the majority of the fiber
detachments occur nearer to the head region than the tail (fig 14). These embryos also
exhibit very short and wide myotomes. The embryos from the EtOH treated HS Paxillin
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embryos with the domain knock outs also appeared short and stumpy when viewed under
a dissecting microscope. Control embryos did not express this phenotype, implicating this
happening in response to the EtOH treatment. Potential reasons for these differences will
be discussed further in the discussion.
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Discussion
The results from this these experiments are not conclusive since every experiment
had something go wrong – not enough controls, not enough experimental embryos,
contamination, etc. However, these experiments do give insight into the dilution of EtOH
that is sufficient to induce dystrophy as well as allude to some interesting differences
between the different Paxillin transgenic lines.
Investigating Different EtOH Dosages:
There was a difference of 14.6% in the responses of the β-actin Paxillins and the
HS Paxillins to 1.5% EtOH. This discrepancy across the lines makes studying the ability
of overexpression of Paxillin difficult using EtOH. More surprisingly, the non-heat
shocked HS Paxillins at 1.5% EtOH having seemingly healthy muscle suggests an
inconsistency with the EtOH treatment since this was the same dose on the same line.
This could be due to the heat shock process facilitating fiber detachment by stressing the
muscle. The Henry Lab recently determined that the temperature of 42 ̊ C may be much
higher than the level the embryos can withstand before muscle formation is affected. A
shorter exposure time or a lower temperature may be required to avoid malformations.
Investigating the Necessity of the LD2 Domain in Ameliorating Dystrophy:
The heat-shocked HS Paxillin (-LD2) GFP embryos that were treated with 2%
EtOH that both fluorescing and non-fluorescing (were not transgenic) showed extreme
dystrophy. Not only did they have an unusually high amount of fiber detachments, but
most of the dystrophy was seen anteriorly more frequently than posteriorly. Under
normal circumstances fiber detachments are more numerous in the tail region around
myotomes 10-15. These embryos with 2% EtOH treatment had fiber detachments
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occurring more frequently in the anterior region around myotomes 5-10. This could be
occurring in response to the age of the muscle cells. Zebrafish embryos develop in a head
to tail fashion, thus the muscle cells in the tail are much younger than the muscle cells
near the head. Perhaps the older muscle cells are more sensitive to the EtOH treatment
than the younger ones.
The contamination of the dishes must also be regarded when trying to determine
the cause of the unusually severe dystrophy. The Henry Lab has observed that
contamination in the dishes generally results in curled embryos after hatching from the
chorion. In most cases motility is negatively affected. The control groups for this
experiment, heat shocked 0% EtOH and non-heat shocked 0% EtOH, had straight,
healthy looking bodies before fixing at 72hpf. Some of the EtOH treated embryos had
curled or stumpy bodies, but this has also been observed with EtOH treatment when there
was no contamination present. However, the EtOH treatment may contribute to the
contaminating microorganisms thriving better than in ERM solution alone and result in
severe dystrophy. This is only conjecture and cannot be validated without further testing.
Only two embryos fluorsced (were transgenic) which is too small of a sample to
be able to glean any information from. Furthermore, although the transgenic HS Paxillin
(-LD2) did not rescue dystrophy this cannot be linked to a lack of an LD2 domain since
the full length HS Paxillin embryos also could not rescue dystrophy with EtOH treatment.
Thus, domain knock outs cannot be studied using EtOH treatment as a means to induce
dystrophy. This is more evident from the results of the next section.
Investigating Paxillin Overexpression with LD2 or LD4 Domain Knock-outs:
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It was very unfortunate that all of the HS Paxillin embryos with the LD2 and LD4
domains knocked out died since a comparison of the two had the potential to yield
interesting results. However, since the HS Paxillins that survived and had full length
Paxillin had a 60% occurrence of dystrophy for 10 embryos, it is evident that Paxillin is
unable to rescue dystrophy at all that is caused by EtOH. Thus, different methods will
have to be implemented in future studies to study the different domains of Paxillin and
amelioration of dystrophy.
Here I will hypothesize some of the reasons behind the trends we observed (if one
temporarily ignores the caveats of the experiments). The major issue with using EtOH
treatment was that it was extremely inconsistent. A dose that was sufficient to induce
phenotypic symptoms of muscular dystrophy in one experiment would annihilate whole
dishes of embryos when it was used for another. This suggests that EtOH is overall toxic
to the zebrafish embryos. Because of this, there is a limit to the amount of EtOH they can
withstand, but the sensitivity to EtOH may vary depending on the clutch.
One possible reason for this variation in response to the treatment may be timing
of hatching from the chorion. The chorion is a thin membrane that envelops and protects
developing embryos until about 48-72hpf when they hatch.[12] The embryos that perished
in the HS Paxillin experiments with 2% EtOH were alive at 48hpf and dead when
checked at 72hpf. It is possible that the chorion is non-permeable or semipermeable to
EtOH, thus the embryos were exposed to greater concentrations of EtOH after hatching.
Since there is a lot of variability in the timing of hatching, this may have resulted in the
variability of the effects of EtOH. The embryos that hatched later may have had a shorter
exposure time to EtOH and had severe dystrophy, such as the heat shocked HS Paxillin (-
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LD2) GFP embryo seen in figure 9. Alternatively, the embryos that hatched earlier would
have had a longer exposure time to EtOH and died from the toxicity. This is only a
hypothesis and would require further testing.
There is also potentially a difference in the sensitivity of the different lines of
Paxillin transgenics. In the last experiment that was conducted, the HS Paxillin (-LD2)
and the HS Paxillin (-LD4) embryos died while the HS Paxillin embryos survived. This
may suggest that the embryos are more sensitive to EtOH treatments when the LD2 and
LD4 domains are knocked out. However, I was identifying transgenic embryos by
looking for fluorescing MTJs after they were fixed during the imaging process, so it is
not certain whether all the embryos in those dishes were transgenic since they died and
degraded before they could be imaged.
There is also the issue that Paxillin was unable to rescue dystrophic embryos in
these experiments. Previous studies that used overexpression of Paxillin to ameliorate
dystrophy used morpholinos that targeted dystroglycan to induce dystrophy.[9] Since
EtOH treated fish could not be rescued with Paxillin overexpression, it appears it is
working via some other pathway. Additional evidence of this is seen in the body shape of
the embryos that perished and in some of those that survived EtOH treatment. These
embryos had very short, stumpy bodies with wide myotomes (fig 12). These embryos
look very similar to laminin mutants that are missing laminin-111.
If EtOH is affecting laminin and not dystroglycan (which we previously targeted
with MOs) this may explain why Paxillin cannot help ameliorate dystrophy. Previous
studies associated overexpression of Paxillin with an increased polymerization of laminin
at the MTJ, which improved cell anchorage to the basement membrane.[9] If EtOH
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directly or indirectly disrupts laminin to a greater extent, then Paxillin overexpression
might not be sufficient to ameliorate dystrophy. However, there are some inconsistencies
in that not all embryos displayed the same stumpy tail phenotype. It was, like all other
aspects of EtOH treatment, varied per each trial. The HS Paxillin (-LD2) embryos and the
HS Paxillin embryos from the EtOH dosage experiment did not display this phenotype
(fig 9).
We cannot make any conclusive hypotheses about the LD domains of Paxillin
because the EtOH treatment was so unreliable. However, the results do give some
inclinations about the potential sensitivity of these domains that we can keep in mind
going forward with a different approach. These experiments have also given rise to some
new hypotheses about EtOH treatment that could guide further studies.
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Figures

Figure 1. 72hpf β -actin Paxillin treated with a 1.75% dilution of EtOH. Fiber detachments
are present. This embryo also has damage to the muscle cells that was inflicted during the
deyolking process.

Fig 2. 72hpf β -actin Paxillin treated with 2% EtOH. Muscle cells appear wavy and fiber
detachments are present.
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Figure 3. 72hpf β –actin Paxillin treated with 2% EtOH. Although there are no visible fiber
detachments, the muscle cells appear wavy.
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Figure 4. Graph of the percent of HS Paxillin and β-actin Paxillin embryos with dystrophy
at 72hpf. This was merely preliminary data that was lacking controls, however it does suggest an
inconsistency with EtOH treatment both across different Paxillin transgenics lines as well as
within the same lines at the same dose.
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Figure 5. 72hpf Non-heat shocked Paxillin embryo 0% EtOH, myotome 10. There are no
fiber detachments and the muscle cells appear straight and uniform.

Figure 6. Heat-shocked HS Paxillin 0% EtOH, myotome 5. There are a large amount of fiber
detachments on four myotomes.
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Figure 7. Graph of the percent of HS Paxillin (-LD2) GFP embryos with dystrophy at
72hpf. This graph takes into consideration the average percent of dystrophy across all embryos in
each group. There was one outlier in the HS Paxillin 0% EtOH group that had dystrophy,
resulting in a 6% average that misrepresents the group.
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Figure 8. Graph of the average number of myotomes with dystrophy for HS Paxillin (-LD2)
embryos at 72hpf. This graph takes into account the average number of myotomes all of the
embryos in each group had. The HS Paxillin 2% EtOH that fluoresced is misleading because
there were only two embryos (one with dystrophy on 19 myotomes and one with no dystrophy).
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Figure 9. 72hpf heat shocked HS Paxillin (-LD2) GFP non-fluorescing embryo with 2%
EtOH treatment. The image starts at myotome five. The dystrophy is so severe that is nearly
impossible to see myotome boundaries.
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A

B

Figure 10. 72hpf heat shocked HS Paxillin (-LD2) GFP fluorescing embryo with 2% EtOH
treatment. The image stars at myotome five. In image A The red staining depicts F-actin and the
green depicts GFP. The embryo was curled, so the image cuts off at the top. Image B is the
phalloidin stain in grey scale. There are severe muscle detachments.
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Figure 11. 72hpf heat shocked HS Paxillin control with no EtOH treatment, myotome 10.
Muscle development appears healthy and there is no evidence of fiber detachments.
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B

Figure 12. 72hpf heat shocked HS Paxillin fluorescing (transgenic) embryo with 2% EtOH
treatment, myotome 8. Image A shows GFP (demonstrating the embryo is a transgenic) in green
and F-actin in Red. Image B shows only the red phalloidin staining for F-actin so fiber
detachments are more visible.
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Figure 13. Graph of the percent of 72hpf HS Paxillin embryos with dystrophy n = 10. 60%
of the group that was treated with 2% EtOH had fiber detachments. None of the embryos that
were not treated with EtOH had fiber detachments.
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B

Figure 14. 72hpf heat shocked HS Paxillin fluorescing (transgenic) embryo with 2% EtOH
treatment, myotome 15. Image A shows GFP (demonstrating the embryo is a transgenic) in
green and F-actin in Red. Image B shows only the red phalloidin staining for F-actin so fiber
detachments are more visible. This is the same embryo from figure 14 imaged in the tail region to
demonstrate that fiber detachments occur more frequently anteriorly than posteriorly with EtOH
treatment.
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Appendix
All procedures involving zebrafish (Danio rerio) described here are reviewed and
approved by the IACUC at the University of Maine
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